Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pick any number you want, I think you get my point! We are talking billions here, and we are fretting over 17.5 million.
We all want financing for nothing. Unfortunately, that will NEVER happen. If LP were to partner for 100 million, there would be naysayers saying that she gave away the company. There will always be problems for some. Financing is a necessary evil for any public company, and biotechs burn through it pretty quickly, especially during trials. If we can't stand the heat, and we don't like the way things are being done, then you are overexposed, and you need to sell some or all of your position.
UPS would indeed be a positive. I am wondering though, what it would do for the share price? DHL, the largest shipper in the world did not move the needle, although something is to be said for the confidence of the top 3 shippers in Cryoport.
Flipper, Thank You.
Flipper,
I am really missing something here. Why is it that they had 312 patients in the trial and the events were 66, 88, and 110. Now with 36 more patients, the first interim goes from 66 to 148. The primary endpoint is changed from 110 events to 248? This is a massive change in the primary endpoint. Why in the world did they do the first interim analysis at 66 then? If I am missing something you have already posted,I am sorry. Please enlighten me! TIA
Maybe this is the way to silence your buddy AF...Just kidding Afford! This way they are not shouting it from the rooftops and trying to pump the stock. They are giving an update at a conference of their peers....and the rest of us get a look too. You will have to be paying attention to Northwest to find out about it, but if the info is good, I would imagine word will get out......
Fox,
I thought the same thing when I read this PR. It also seems unusual that an 8-k was filed for this. Maybe trying to drive home the fact of expanded manufacturing without invoking a negative response? Any thoughts, anyone?
Monday was the last day the offering was open. We need to see how much money they raised and from whom. With Fed Ex and DHL putting this much confidence in them, I do not think they have doubts about their survival.
With FedEx and DHL prominently onboard, can UPS be far behind, or will they be left behind. I does appear that Cryoport is the go to company for cryogenic shipping, at least with the dominant players.
It is also 4th of July week and no one is around. There is little news and the week is boring. ZZZZZZZZZZZZ
No, I do not.
Talking to my broker, the answer he give is that the float is settled as of the close on Friday. This is why the huge volume at the close as float is balanced by the funds. They now have the required amount of shares for the Russell 3000. Remember, people buy and sell shares of that index daily. But, the buying and selling to get into the index is now over, IMBHO. (In my brokers humble opinion....LOLOL)
This is the rebalancing of the Russell 3000. These funds bought too many or not enough shares, and it all washes out at,or after the close. The price is extremely volatile. It is over now, and normal market conditions will take over on Monday.
I keep hearing about the personalization of medicine in the coming years. With the advance of immune therapies, it is estimated that half of the new treatments will need shipping at cryogenic temperatures. This is a portion of a post on another board about the manufacture, storing and shipping of a cancer vaccine. I thought it was interesting about the location of the plant, especially after watching the video. The whole post can be found here:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=103663253
The regulatory requirements for living cell products are exceptionally difficult to meet in part because the products are often personalized. Cognate has an impressive regulatory track record. Over the last decade it has been responsible for manufacturing product for more than 20 INDs for living cells products and all of these INDs have been approved by the FDA. Impressively, no client of Cognate has been put on clinical hold due to manufacturing issues.
Northwest and Cognate Biosciences have spent over ten years pioneering a unique method of batch manufacturing for DCVax-L that is based on producing at least 3 years of treatments from one batch manufacturing cycle. They have developed special cryopreservation methods which enable a multi-year quantity of product to be frozen and kept frozen for years while maintaining its potency. This multi-year batch manufacturing and cryopreservation are essential elements that result in high costs only being incurred one time. Thereafter, the stored cryopreserved product is effectively an off the shelf product with little marginal cost. This should allow Northwest to price DCVax-L comparable to or below current biologics and small molecules used in cancer treatment and still achieve attractive profit margins.
Cognate’s facilities are located near the airport in Memphis, Tennessee to take advantage of worldwide air shipping hubs for both Federal Express and UPS. The logistics of personalized medicine requires that tumor samples and dendritic cell precursors gathered in blood drawn be flown in for processing and frozen finished product is then flown out. Cognate currently has capacity to service about 300 DCVax-L patients per year, which is sufficient for the phase III trial. However, Fraunhofer and King’s College London will add additional capacity. The current manufacturing facilities could be modularly scaled up over time to a capacity of 5000 patients per year; Dendreon launched Provenge with capacity of 2000 patients. This would support first year revenues from newly treated patients of $350 million. Also, it should be noted that the injections in years 2, 3 and beyond are manufactured with the injections for the first year and are available off the shelf.
Nice find...Things are really looking up for us.
As an aside, I was in San Diego last week, and in the Anahiem area.
Went by Cryoport in Lake Forest. No large signage, building very plain and industrial. My wife says this doesn't look like much. I went on Saturday, so I coould not go in as they were closed. But after seeing this video, and the inside of the building, I am impressed. If fed ex has this much confidence in them, something tells me we should too....
He may be writing an article about NWBO, but the article would have nothing to do with said interview. Laser777
Flip,
Totally agree with you, he should resign. Unfortunately, MDA makes a lot more money on Big Pharma than on Northwest, so there wishes and desires will always come first.
Cramer the Clown, and AF probably represent Big Pharma also.
This was a coordinated attack by the Clown and AF, and unfortunately it is probably not over. Can you even think this would have happened had big pharma already partnered with Northwest?
Maybe they are telling Northwest to partner or else. I hope Ms. Powers flips them her middle finger!
You are dealing with AF here. Remember you have HIS side of the interview. You have NO idea what else was said, and left out of the article.
You can conduct interviews in any fashion you wish. The way the questions are posed, you can get the answers you want. This oncologist is not saying the PR's from Northwest are false or made up. He is saying they have not analyzed the data yet.
But Buzdar said investigators at MD Anderson and the two other hospitals conducting the DCVAX-Direct study have not reviewed or analyzed data at all because patients are still being enrolled and treated. The statements being made by Northwest Bio about DCVax-Direct are derived from patient case report forms, which the hospitals are obliged to send to the company because it sponsored the study.
So this Northwest info IS TRUE, but they have not analyzed it yet.
And some of you thought AF was on our side. THAT WILL NEVER HAPPEN!
An opinion is one thing.....A bunch of made up distortions, and lies is another.
Could Adam F. be a second EDGE? There is a reason for his obsession with Northwest, and I think you could be spot-on with your analysis.
That is the point Basin Street Blues is trying to make, by saying that this is the best "EDGE" in the market he has ever seen.
Quote:
I got lost the data modelling conversations earlier , I'm sure they make sense to some
of you ,and give comfort when panic sets in, and believe me Id love it to be announced
tomorrow but honestly just hang on to one fact :
Believe me I am on the board of a Germany company,( Financial services not Pharma ) there
is not a single chance the PEI gave this exemption without beint 100% sure it works . WE
know from some of the stella work other posters have done that the US trial control bodies ARE at liberty to share hitherto secret information with overseas Governments and that coupled with local Cologne results got the sign off. Germans people and German industries simply do not take risk , its against their very nature , they know it works better than the current Soc with out any side effects and they approved it . there is no higher benchmark than Germany
And one day the Market will care.....
BRAVO......
This is it in a Cliff Notes Version.
I was interested in that also. What was the minimum purchase?
I will agree with this....Now that they have signed this offering and it is open till June 16th, if they released news and the price went up, it would make it easier to fill the allotment. That would be great. But IF they released news before the offering was signed, the offering would be dead. The people who buy offerings keep the price down by shorting the stock until the offer is done. Then they replace those shares with the shares they buy in the offering. They will also tend to sell more shares to get their money back, and then keep the warrants. This is what has been keeping a lid on the price of Cryoport, in the face of really good news. And, another gift From Wasserman, Shetlton and Rathmann, is that there is only 8 warrants to 30 shares. We hopefully won't have to work through so many shares after the offering!
I agree with you. It is common when an offering is in progress, that material news is suppressed as to not move the price of the stock dramatically. Also, large companies will not make a commitment to a company that does not have the financial resources to follow through on the deal, or has a danger of going BK. After the money is raised, they should find it easier to land the big fish. This is why the deal with Zoetis, (Pfizer) was a huge deal with the stock trading at 15 cents. Although they already used their own dewars for cryogenic shipping, they gave control and trusted a company that was almost insolvent. This is probably why we only heard of the news through a filing, not a PR. They need to raise this money to expand the business. Then we should see very nice sequential quarter over quarter growth.
Now you hit it! He is what is termed a "friendly basher." Tries to be nice and friendly to gain confidence all while bashing away. No matter what he posts, the overall tone is negative. Do you really believe he is long with the negativity of his posts? This is why I ask why everyone here continues to "Feed this Troll."
Hands seem to be getting weak here. Just what the shorts love.
Maybe we take a look at this post again, as this is the best reason to stay invested....
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=102191213
I agree totally about Shelton, but let's not forget about Wasserman. He took Stambaughs garbage heap,weeded out the dead weight, and formed this team. Without him, Cryoport was dead!
There are plenty of people, with the share price above ten dollars, who will exercise the warrants, sell the stock, and move on to something else.
After reading through this 8-K, it appears that the bridge notes are converted to shares at $.36 per share. The offering is then open to new investors until June 16th, at a basic price of $.40 per share. The units sell for 12 dollars and consist of 30 shares and 8 warrants at an exercise price of $.50. If you raise 10 million dollars it will consist of 25 million shares. Hopefully this is the last raise......
SW,
I agree with you. They have turned the corner big time. As you stated at the time, the deal with Liventa Bio Science is really bigger than most realize, and a major turning point for the company.
I believe we will see outstanding sequential growth going forward. With this growth comes pain, as again as you have stated money will be raised, to fuel this growth. They will need a large influx of new dewars to support this growth. Seems managemant is trying to do any raise at .50 or above. In my opinion, this raise is keeping a lid on the share price, a kind of tug of war. Lets hope Rathmann and Co. win!
I, for one missed this in the last 10-Q:
. In July 2013 the agreement was amended to expand Cryoport’s scope to manage all logistics of Zoetis’ key frozen poultry vaccine to all Zoetis’ international distribution centers as well as all domestic shipments of this vaccine. In October 2013 the agreement was further amended to further expand Cryoport’s services to include the logistics management for a second poultry vaccine.
Well said
Any ideas why we are marching?
Looks like no 10Q for 15 days....
http://www.sec.gov/Archives/edgar/data/1124524/000114420413062067/0001144204-13-062067-index.htm
Company not bending shareholders over like Stambaugh....
Raising money through bridge notes until better deal avsailable to shareholders...Mr Rathman gets on board!
2013 Bridge Notes
In the fourth quarter of fiscal 2013, the Company issued to certain accredited investors unsecured convertible promissory notes (the “Bridge Notes”) in the original principal amount of $1,294,500, pursuant to the terms of subscription agreements and letters of investment intent.
The Bridge Notes accrue interest at a rate of 15% per annum from date of issuance until January 31, 2013 and at a rate of 5% per annum from February 1, 2013 through the date of payment, in each case on a non-compounding basis. All principal and interest under the Bridge Notes will be due on December 31, 2013. Debt financing costs of $116,505 comprised of agent commissions were recorded in other current assets and are being amortized to interest expense under the straight-line method which approximates the effective interest method over the term of the notes. During the year ended March 31, 2013, the Company amortized $8,671 to interest expense.
In the event the Company designated and issued preferred stock while the Bridge Notes were outstanding, the Bridge Notes were convertible into shares of such preferred stock at a conversion rate equal to the price per share paid to the Company in connection with the issuance of such preferred stock at the option of the holder of the Bridge Notes. The Company was unable to value the conversion feature of these Bridge Notes given the absence of a conversion rate the convertability of the Bridge Notes being contingent on the completion of a preferred stock transaction.
Effective on April 19, 2013, the Company amended the Bridge Notes whereby in the event that the Company issues one or more types of equity securities (a “Transaction”) before the maturity of the Bridge Notes, the holder may elect to convert all or a portion of the principal and accrued interest into shares of such equity securities issued in a Transaction at a conversion rate equal to the price per share paid to the Company in connection with the issuances. The Company is required to notify the Bridge Notes holder of a Transaction within 10 days of each Transaction and the Bridge Notes holder has the option until the later of (a) ten (10) days after such notices or (b) December 15, 2013 to elect in writing to convert the Bridge Notes.
Note 16. Subsequent Events
In the first quarter of fiscal year 2014, the Company issued to certain accredited investors an additional $608,751 in Bridge Notes with the same terms as described under Note 8. These additional Bridge Notes include $100,000 from one of our Board Members, Richard Rathmann. As of June 17, 2013 the total principal amount of the Bridge Notes was $1,903,251.
In May 2013, the Company issued 500,000 shares of common stock upon the exercise of options at an exercise price of $0.20 per share for total gross proceeds of $100,000.
A Nice News Release from Amgen today.
Pay attention to paragraph 3.
ew Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer
Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response
PR NewswirePress Release: Amgen – 20 hours ago
Email
Print
RELATED QUOTES
Symbol Price Change
AMGN 106.06 -1.36
THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating mutations in KRAS (beyond exon 2) and mutations in NRAS, collectively referred to as RAS.
"Amgen helped establish KRAS gene mutation as a biomarker for lack of response to anti-EGFR treatment," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The identification of new biomarkers may further help to identify appropriate patients with this incurable disease for such treatment."
The RAS biomarkers were identified in a predefined retrospective subset analysis of the PRIME trial, where RAS was defined as exons 2, 3 and 4 of KRAS and NRAS. Mutational status of tumors was determined by Sanger sequencing in parallel with WAVE®-based SURVEYOR® Scan Kits (CRC RAScan™) from Transgenomic, Inc. (TBIO). In this exploratory analysis, patients with wild-type RAS mCRC who were administered Vectibix in combination with FOLFOX demonstrated an improvement in median overall survival (OS) of 26.0 months compared to 20.2 months for patients treated with FOLFOX alone (HR = 0.78, 95 percent CI, 0.62-0.99).
Patients with mutant RAS tumor status had inferior progression-free survival (PFS) (HR = 1.34, 95 percent CI, 1.07-1.60) and OS (HR = 1.25, 95 percent CI, 1.02-1.55) when administered Vectibix in combination with FOLFOX chemotherapy versus FOLFOX alone. These results suggest that RAS mutation status beyond KRAS may be predictive of negative outcomes in patients receiving Vectibix plus FOLFOX in mCRC. Amgen is working to inform investigators and physicians of this important new safety information, as well as working with regulatory agencies regarding appropriate communication of the outcomes of this analysis.
Results of this study will be presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting on Tuesday, June 4, 8:00 a.m. - 12:00 p.m. CDT, S405 (Abstract No. 3511; Poster Discussion).
ICE COLD PCR Abstract
Pay Special attention to the conclusions. They speak volumes on this.
Abstract:
Background: A variety of methods for isolation of CTCs of epithelial origin are available; most employ antibodies to epithelial cell adhesion molecule (EpCAM). Using classic phenotypic definition, a CTC is nucleated, cytokeratin CK(+), CD45(-) cell. However, some CTCs may elude capture as they originate from primary tumor cells which have undergone epithelial-mesenchymal transition (EMT). We report here the use of ApoStream, a novel dielectrophoresis field-flow-assisted, antibody-free method to isolate CTCs from blood. Methods: Blood was collected from consented NSCLC patients and processed using ApoStrea. For CTC enumeration comparison, CellSearch FDA-approved kit was used. Isolated cells were evaluated with multiplexed immunofluorescent assay and laser scanning cytometry analysis were applied to identify multiple combinations of positive and/or negative staining for CK/CD45/DAPI and EpCam. To determine specific EGFR mutations from captured CTCs, samples were analyzed using Improved and Complete Enrichment with CO-amplification at Lower Denaturation temperature (ICE COLD-PCR). Results: Blood samples from 32 NSCLC patients and 3 healthy volunteers were processed. ApoStream isolated 0 to 65 CK(+)/CD45(-) CTCs(n=32) and CellSearch isolated 0 to 13 EpCAM(+)/CK(+)/CD45(-) CTCs(n=7). Additionally, ApoStream™ recovered 37-3536 CK(-)/CD45(-) and 4-10702 CK(+)/CD45(+) cells. EpCAM expression was detected in 7-100% of CK(+)/CD45(-) and 0-5% of CK(-)/CD45(-) cells, and 18-100% of CK(+)/CD45(+) cells. EGFR mutations [exon 19 deletion and exon 21 L858R] were determined and found to be concordant when compared to tumor tissue analysis by Sanger sequencing. Conclusions: The ApoStream platform enriched EpCAM(+) and EpCAM(-) CTCs from the blood of NSCLC patients demonstrating utility in recovering cancer cells with multiple phenotypes. From recovered CTCs, detection of EGFR mutations was possible indicating the clinical relevance and potential utility of CTCs as an alternative to tissue biopsy. Complete mutation analysis will be presented.